Ankyrin-B (AnkB) is scaffolding protein that anchors integral membrane proteins to the cardiomyocyte cytoskeleton.
Introduction
Ankyrin-B (AnkB) is a large 220 kDa scaffolding protein that plays a critical role in tethering the contractile machinery (i.e. ion channels and transporters) in a specialized region of the cardiomyocyte cell membrane (Mohler et al. 2007b ; Koenig and Mohler 2017; El Refaey and Mohler 2017) . Variants in the ANK2 gene can lead to Ankyrin-B syndrome, which is mainly characterized by a predisposition to cardiac arrhythmia and an increased risk of sudden cardiac death (Mohler et al. 2004 (Mohler et al. , 2007b . The phenotype of AnkB +/− mice partially recapitulated pathologies observed in human ANK2 gene loss of function variants, including predisposition to arrhythmia (Mohler et al. 2007a) . AnkB knockout mice are postnatal lethal, whereas AnkB knockout cardiomyocytes display abnormal contraction, as well as irregular calcium homeostasis (Scotland et al. 1998; Mohler et al. 2002) , which could result from altered development at the cellular and molecular levels.
We recently reported a new AnkB variant, AnkB p.S646F (ANK2 c.1937 C>T), a mutation in the membrane binding domain (MBD), whose carriers displayed variety of clinical features including long QT syndrome, dilated cardiomyopathy with associated sudden death, congenital heart malformation, Wolff-Parkinson-White syndrome, and seizures (Swayne et al. 2017 ). AnkB p.S646F is similar to other AnkB variants in that it confers susceptibility to cardiac arrhythmia; however, AnkB p.S646F is also uniquely associated with a broader phenotype including structural abnormalities. This suggests that AnkB may play a more prominent role in development and formation of the heart than previously understood. Moreover, changes in AnkB expression levels have been implicated in aberrant cardiomyocyte development (Mohler et al. 2003 (Mohler et al. , 2004 Swayne et al. 2017) . Our previous study revealed that expression of AnkB p.S646F was significantly reduced relative to wildtype AnkB (Swayne et al. 2017) . Here, we investigated the cellular degradation pathway for AnkB and the impact of the AnkB p.S646F variant on cardiomyoblast growth and viability. Our findings shed important new light on AnkB in the context of cardiomyocyte biology and pathophysiology.
Methods

Cell culture
The H9c2 rat ventricular-derived cardiomyoblast cell line was obtained from the American Type Culture Collection (ATCC CRL-1446). H9c2 cells were cultured in Dulbecco's Modified Eagle Medium (DMEM, ThermoFisher Scientific, Burlington, CA) supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin, and 100 g/mL streptomycin at 37°C in 5% CO 2 . Cells were passaged at 70% confluence. H9c2 cells were seeded at 16 667 cells/cm 2 24 h prior to transfection, as per manufacturer's protocol (Polyplus-transfection ® SA/VWR, Edmonton, CA). The wildtype ankyrin-B-pAcGFP-n1 and mutant ankyrin-B p.S646F-pAcGFP-n1 were created as previously described (Swayne et al. 2017) .
H9c2 cells were differentiated as previously described by Ménard et al. (1999) . Briefly, H9c2 cells were seeded at 8333 cells/ cm 2 and transfected the next day. One day after transfection, media was changed to DMEM with 1% FBS, 10 nmol/L all-trans retinoic acid (RA), 100 U/mL penicillin, and 100 g/mL streptomycin (Diff DMEM). Three days after transfection, media was replaced with Diff DMEM with 500 g/mL of G418 to maintain heterologous gene expression.
Determination of protein degradation pathway
To determine the degradation pathway, H9c2 cells were treated 6 h after transfection with 0, 25, or 50 nmol/L of the proteasome inhibitor PS-341 (ThermoFisher Scientific, Burlington, CA) and 0, 10 or 25 nmol/L of the lysosome inhibitor Bafilomycin A (BafA, Millipore Sigma, Oakville, CA) for 12 h until cell lysis for Western blot analysis. To test if AnkB p.S646F levels could be rescued by proteasomal inhibition, H9c2 cells were transfected with either wildtype AnkB or AnkB p.S646F-GFP and treated with 0 or 10 nmol/L PS-341, 6 h after transfection. Cells were lysed 12 h after PS-341 treatment for Western blot analysis. For H9c2 differentiation, cells were collected 5 days after transfection and were treated with PS-341 for 12 h prior to collection.
Western blotting
Samples were homogenized in RIPA buffer (10 mmol/L PBS (150 mmol/L NaCl, 9.1 mmol/L dibasic sodium phosphate, 1.7 mmol/L monobasic sodium phosphate), 1% IGEPAL, 0.5% sodium deoxycholate, and 0.1% SDS) supplemented with protease inhibitor cocktail at 1 L/ 10 6 cells (stock: 0.104 mmol/L 4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride, 0.08 mmol/L aprotinin, 4 mmol/L bestatin hydrochloride, 1.4 mmol/L N-(trans-epoxysuccinyl)-L-leucine 4-guanidinobutylamide, 2 mmol/L leupeptin hemisulfate salt, and 1.5 mmol/L pepstatin-A; Millipore Sigma, Oakville, CA), PMSF at 2 L/10 6 cells, and 1 mmol/L EDTA, passed through a 27-gauge needle twice, and incubated for 30 min on ice. Cell lysates were then centrifuged at 4°C for 20 min at 12 000 rpm and supernatant was collected. Lysates were heated for 5 min at 95°C under reducing conditions (dithiothreitol (DTT) and ␤-mercaptoethanol), separated by SDS-PAGE and transferred to 0.2 m pore PVDF membrane (Bio-Rad, Mississauga, CA). The membrane was blocked with 5% non-fat milk in PBST or TBST and then incubated with indicated antibodies in the blocking solution. Primary antibodies used include anti-GFP (1:8000 -1:128000; ThermoFisher Scientific, Burlington, CA), anti-␤-actin (1:8000 -1:128000), and anti-AnkB (1:500; ThermoFisher Scientific, Burlington, CA). Secondary antibodies were horseradish peroxidase (HRP)-conjugated AffiniPure donkey anti-rabbit IgG (1:2000) and HRP-conjugated AffiniPure donkey anti-mouse IgG (1:4000 -1:8000), both were from Jackson ImmunoResearch, West Grove Pennsylvania, USA. Bands were visualized with Clarity Western enhanced chemiluminescence substrate (Bio-Rad, Mississauga, CA) and quantified by densitometry analysis with ImageJ (version 1.45) (Schneider et al. 2012) .
Immunocytochemistry and confocal microscopy
H9c2 cells were seeded onto poly-D-lysine laminin coated coverslips (NeuroVitro, Vancouver, USA) at 8333 cells/cm 2 and transfected 24 h after seeding. Forty-eight hours after transfection, coverslips were fixed for 10 min with warmed 4% PFA supplemented with 4% sucrose, followed by three washes with PBS and stored in PBS at 4°C until used. A subset of coverslips was washed with PBS and incubated with wheat germ agglutinin (WGA) Alexa Fluor™ 647-conjugate (W32466, Thermo-Fisher) in 1× HBSS (14185052, Thermo-Fisher) for 5 min, washed three times in PBS, fixed with 4% PFA and 4% sucrose, and then stored at 4°C until used. For immunocytochemistry, cells on coverslips were permeabilized with 0.25% Triton-X for 10 min, blocked with 10% donkey serum (DS, Jackson ImmunoResearch), 1% BSA, and glycine (22.52 mg/mL) in PBST for 30 min at room temperature. Following blocking, coverslips were incubated overnight at 4°C with primary antibodies, anti-Ki67 (1:200, BD Pharmingen, San Jose, CA) and anti-AnkB (1:200), diluted in 1% BSA and 5% DS in PBST (antibody buffer), washed three times in PBS (10 min each), and incubated with secondary antibody, AlexaFluor 586-conjugated donkey anti-mouse IgG (1:600; A10037, Thermo-Fisher), in antibody buffer. Acti-stain 670 phalloidin (PHDN1-A, Cytoskeleton, Inc.) was used for coverslips that were not labelled with WGA. Qualitative determination of AnkB-GFP and AnkB p.S646F-GFP localization was done by acquiring high-resolution confocal images (2048 × 2048, pixel size: 0.142 m) using a Leica TSC SP8 microscope and a 40× oil-immersion objective (1.40 NA, pinhole 1.0 AU). For Ki67+ nuclei quantification, high-resolution images (2048 × 2048, pixel size: 0.568 m) were acquired using a 10× dry-objective (0.3 NA, pinhole: 4 a.u.). Analysis of Ki67+ nuclei was performed within the open-source ImageJ distribution Fiji (Schindelin et al. 2012 ) with the following custom-made macro to obtain the number of total nuclei and Ki67+ nuclei, GFP area, and F-actin area from the acquired images:
Run ("Gaussian Blur…", "sigma = 2 scaled stack"); SetAutoThreshold("IsoData dark"); //run("Threshold…"); setOption("BlackBackground", true); run("Convert to Mask", "method = IsoData background = Dark calculate black"); run("Make Binary", "method = Default background = Default calculate black"); run("Close-", "stack"); run("Watershed", "stack"); run("Analyze Particles…", "size = 100-1 000 000 show = Outlines display clear summarize add stack"); All representative images were created using Adobe Photoshop CS6 (Adobe Inc.) and subjected uniformly to a Gaussian Blur of 0.5 pixels and contrast and (or) brightness adjustments for display purposes only.
MTT assay
Cells were transfected with wildtype AnkB or AnkB p.S646F-GFP plasmid or treated with a toxic dose of 300 g/mL cycloheximide (as a control for apoptosis) 24 h after plating in a 96 well plate. The MTT (3-(4,5-dimetylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was performed 48 h after transfection or treatment, as per the Vybrant MTT Cell Proliferation Assay Kit "Quick Protocol" (V1354; Invitrogen by ThermoFisher Scientific). Briefly, each well was replaced with 100 L fresh media and incubated with 10 L of the 12 mmol/L MTT stock solution. After labelling, all but 25 L of the culture medium was removed, 50 L of DMSO was added, and the cells were incubated at 37°C for 10 min. Absorbance was read at 540 nm (Infinite ® 200 PRO microplate reader, Tecan Life Sciences). All absorbance values were normalized to blank (vehicle control media, containing no cells). One N represents the mean of 9 scans per well, and 8 wells were analyzed for each condition (N = 8).
Trypan Blue proliferation assay
Cells were replated 24 h after transfection at a density of 355 cells/cm 2 . Trypan Blue dye (0.4% Trypan Blue in PBS; HyClone™) was used as per the manufacturer's protocol to count live and dead cells. The first cell count began 6 h after replating and every 24 h thereafter for a total of five timepoints.
Flow cytometry
Cells were plated at a density of 8333 cells/cm 2 and transfected with either wildtype AnkB or AnkB p.S646F-GFP 24 h after seeding. Cells were collected 48 h after transfection using Versene (Gibco) and the cell suspension was transferred to a 96 well plate at three wells per sample and three samples per condition. Samples were analyzed using Guava easyCyte 5HT (Millipore).
Statistical analysis
All results are represented as mean ± standard error of the mean (SEM). Statistical analysis was performed with Prism 7 for Mac OS X (version 7.0a, GraphPad Software, Inc.) and is described 
Results
AnkB p.S646F variant increases AnkB targeting for proteasomal degradation in undifferentiated but not in differentiated H9c2 cells
To study how AnkB levels are regulated in cardiomyoblasts, we expressed wildtype AnkB in the H9c2 cardiomyoblast cell line. To distinguish between two primary pathways of protein degradation, wildtype AnkB-GFP expressing H9c2 cells were incubated with a proteasomal inhibitor, PS-341, or a lysosomal inhibitor, Bafilomycin A1 (BafA) (Fig. 1A) . The level of expression of AnkB-GFP was determine by Western blotting using an anti-GFP antibody ( Figs. 1Aii and iv) . Treatment with PS-341 (25 nmol/L or 50 nmol/L) increased the expression level of wildtype AnkB relative to vehicle control (Fig. 1Aii) . Incubation with the lysosomal inhibitor (10 and 25 nmol/L BafA) did not significantly change the expression level of wildtype AnkB compared with vehicle control (Fig. 1Aiv ). We also stripped and reprobed these membranes with anti-AnkB to look at the effect of PS-341 and BafA on endogenous AnkB (Figs. 1Aiii and v) . Using anti-AnkB, PS-341 appeared to produce an even greater increase in AnkB. However, due to the large size of AnkB (220 kDa), it was not possible to resolve endogenous AnkB from exogenous AnkB-GFP, such that the signal reflects both endogenous and exogenous AnkB. These findings suggest the proteasome is responsible for wildtype AnkB degradation in H9c2 cells.
We then sought to determine if inhibition of the proteasome could rescue the reduced expression level of AnkB p.S646F (Fig. 1B) . Consistent with our previous observations (Swayne et al. 2017 ), the expression level of AnkB p.S646F was significantly lower than that of wildtype AnkB (Fig. 1Bii ). Treatment of AnkB p.S646F-GFP transfected H9c2 cells with 10 nmol/L PS-341 elevated the expression level of AnkB p.S646F-GFP to that of wildtype AnkB (Fig. 1Bii) . Similarly, examination with anti-AnkB suggested that PS-341 significantly increased endogenous and exogenous AnkB in both wildtype AnkB and AnkB p.S646F transfected H9c2 (Fig. 1Biii ). Therefore, the expression level of AnkB p.S646F can be rescued by inhibition of the proteasome.
To determine if proteasome inhibition has similar effects in differentiated H9c2 cells, cells were differentiated using low serum and RA (Ménard et al. 1999; Branco et al. 2015) . Notably, in the differentiated state, wildtype AnkB and AnkB p.S646F expression levels were not significantly different (Fig. 2) . Moreover, when treated with PS-341, only wildtype AnkB significantly increased in expression levels, suggesting that PS-341 was unable to rescue AnkB p.S646F levels in differentiated H9c2.
AnkB p.S646F decreases cell viability
To determine the impact of AnkB p.S646F on cardiomyoblast growth, H9c2 cells were transfected with wildtype AnkB or AnkB p.S646F, and cells were counted every 24 h for 96 h in the presence of Trypan Blue (Fig. 3) , which will only enter dead or dying cells whose plasma membrane is sufficiently compromised. Significantly lower numbers of live cells were observed in H9c2 cultures expressing AnkB p.S646F over time (Fig. 3A) . Wildtype AnkB and AnkB p.S646F overexpression produced cell doubling times that were not significantly different (wildtype: 32.5 h, p.S646F: 30.3 h; P = 0.5755 by t test, N = 5), suggesting that this difference in live cell counts over time was not due to differences in cell proliferation. The percentage of dead cells in wildtype AnkB and AnkB p.S646F expressing cultures was plotted across time ( Fig. 3B ) revealing that 6 h after plating (30 h after transfection), AnkB p.S646F expression was associated with ≈19% increase in the percentage of dead cells compared with wildtype AnkB (p.S646F: 41.3% ± 3.9%; wildtype: 21.9% ± 3.9%; P < 0.0001 Bonferroni's multiple comparison; Fig. 3B ).
These results suggest decreased cell viability of AnkB p.S646F expressing cells during the initial lag phase of cell growth.
To further investigate the impact of AnkB p.S646F expression on cell viability in H9c2 cells, we compared the metabolic activity of wildtype AnkB and AnkB p.S646F expressing cells by MTT assay. A toxic dose of CHX (300 g/mL), a protein translation inhibitor (Alvarez-Castelao et al. 2012), served as a positive control for cells with compromised metabolic activity and viability. H9c2 cells expressing AnkB p.S646F exhibited a small but significant reduction in metabolic activity (Fig. 4) . These results support the results of the Trypan Blue assay (Fig. 3 ), suggesting that expression of AnkB p.S646F impairs cell viability.
Confocal fluorescence microscopy revealed that both wildtype AnkB and AnkB p.S646F localized to the membrane and intracellular compartments, as shown by the close association of the GFP and anti-AnkB signals with WGA ( Fig. 5A) . Additionally, we immunostained transfected H9c2 cells with Ki67, which is a marker of proliferating cells (Gerdes et al. 1984) (Fig. 5B) . Notably, AnkB p.S646F transfected H9c2 cultures exhibited a higher proportion of Ki67-positive cells (Fig. 5 Ci) . We also compared cell size between wildtype AnkB and AnkB p.S646F transfected H9c2 cultures using total actin area normalized to the number of nuclei within the same field-of-view and found no significant differences (Fig. 5Cii ). It is important to note that we detected the presence of double nuclei in both wildtype AnkB and AnkB p.S646F cultures, although there were no obvious differences between genotypes (albeit not quantified). Only a small proportion of H9c2 cells were GFP positive (wildtype AnkB-GFP, 4.9%; AnkB p.S646F-GFP, 5.5%).
AnkB p.S646F expresses at lower levels in individual undifferentiated H9c2 cells
To ensure that the lower AnkB p.S646F expression levels seen in untreated H9c2 cells (Fig. 1B) were not simply caused by selective loss of AnkB p.S646F expressing cells (with concomitant expansion of nonexpressing cells), we also measured GFP fluorescence intensity of individual cells using flow cytometry. We observed a shift towards lower fluorescence intensity in cells transfected with AnkB p.S646F compared with wildtype AnkB expressing cells (Fig. 6A) . The mean fluorescence intensity of AnkB p.S646F expressing cells was also significantly lower than that of the wildtype, confirming that on a cellular level, AnkB p.S646F is expressed at lower levels than wildtype AnkB (wildtype: 9.5 a.u., p.S646F: 6.0 a.u.; P = 0.0011 by t test, N = 3; Fig. 6B ).
Discussion
The role of AnkB in the proteostasis of its binding partners in the cardiomyocyte is well established (Mohler et al. 2005; Cunha et al. 2007 ), but our understanding of the proteostasis of AnkB itself is limited. This is critically important for understanding its role in cardiomyocyte biology. Here, we investigated the mechanism of AnkB degradation, as well as the impact of a novel variant AnkB p.S646F on this process and on cell viability in H9c2 rat ventricular cardiomyoblast cells.
We recently showed that AnkB p.S646F is unique in the context of other disease-causing AnkB variants in that it effects AnkB stability (Swayne et al. 2017) . Other variants did not exhibit decreased protein levels when exogenously expressed in cardiomyocytes (Mohler et al. 2007b ). Here, we found that inhibition of the proteasome led to expression of AnkB p.S646F at levels similar to those of wildtype AnkB in H9c2 cells, suggesting that the p.S646F mutation causes AnkB to become targeted for proteasomal degradation. Although we were unable to differentiate endogenous AnkB from exogenous AnkB p.S646F-GFP, wildtype AnkB and AnkB p.S646F transfected H9c2 cells exhibited no significant differences with anti-AnkB (reflecting signal from both endogenous and ectopic AnkB), suggesting AnkB p.S646F does trigger degradation of wildtype AnkB. These findings suggest that the cellular pathology resulting from expression of AnkB p.S646F variant is due to protein dysfunction rather than directly affecting wildtype AnkB stability. In terms of the underlying mechanism of increased AnkB p.S646F proteasomal degradation in the context of immature, undifferentiated H9c2 cells, addition of the hydrophobic phenylalanine residue and resulting tertiary (or quaternary) structural changes could enhance the likelihood of AnkB p.S646F ubiquitination (Schröder and Kaufman 2005; Hetz et al. 2011; Oikawa et al. 2012) . In our previous report, the folding of the purified MBD with the p.S646F mutation was similar to that of the wildtype MBD (Swayne et al. 2017 ), suggesting there was no inherent instability within the MBD caused by the mutation. However, Fig. 3 . AnkB p.S646F results in an early reduction in cell viability. Growth curve of AnkB and AnkB p.S646F-GFP expressing H9c2 cells. Live and dead cells were counted with Trypan Blue 6 h after replating (0 h; equivalent to 30 h after transfection), and every 24 h for 96 h in total. (A) Mean live cell numbers (×10 4 ) across time. There was a significant difference in the number of live AnkB p.S646F expressing H9c2 cells and wildtype (WT) AnkB expressing cells across time. Two-way ANOVA: F [1, 40] = 6.035, P = 0.0185; time: F [4, 40] = 81.86, P < 0.0001; interaction F [4, 40] = 0.5959, P = 0.6676 by two-way ANOVA; Bonferroni's multiple comparisons indicate P > 0.05 between wildtype and AnkB p.S646F for all time points; N = 5). Doubling time for wildtype live cells and AnkB p.S646F live cells were similar at 32.5 h and 30.3 h, respectively. (B) Mean dead cell number as a percent total cell number for wildtype and AnkB p.S646F cultures. Two-way ANOVA: genotype: F [1, 40] = 9.516, P = 0.0037; time: F [4, 40] = 19.33, P < 0.0001, interaction: F [4, 40] = 5.197, P = 0.0018 by; Bonferroni's multiple comparison (****) P < 0.0001; N = 5. These data are included in the MSc thesis of Lena Chen found at https://dspace.library.uvic.ca/handle/1828/9346. the MBD has previously been shown to participate in intramolecular interactions with the C-terminal domain (Abdi et al. 2006) , such that the p.S646F mutation could affect intramolecular interactions of the MBD with the C-terminal domain or intermolecular interactions with post-translational modification machinery or proteins, resulting in relative instability within cells. Resulting from these aberrant intra-or inter-molecular interactions, the p.S646F mutation could increase the association of AnkB p.S646F with E3 ubiquitin ligases to facilitate AnkB degradation. Precisely how AnkB p.S646F leads to increased proteasome degradation will be the focus of future work.
Our characterization of cellular behaviours in wildtype AnkB and AnkB p.S646F expressing H9c2 cells suggest a complex, timedependent effect on viability and proliferation (Fig. 7) . AnkB p.S646F expression led to an increased number of compromised cells, analyzed by Trypan Blue exclusion at 30 h after transfection and MTT assay at 48 h after transfection. Additionally, we observed an increased proportion of actively cycle 48 h after transfection as indicated by Ki67 immunoreactivity. Although we used Ki67 as a binary indicator of cycling cells in our analysis, it should be noted that recent work suggests Ki67 exhibits a graded response, influenced not only by the cycle stage, but also the cell type and length of time in arrest before re-entering cell cycle (Miller et al. 2018) . Future in-depth examination of Ki67 localization and intensity could serve to better understand the impact of AnkB and AnkB variants on H9c2 cell cycle dynamics. Notably, both wildtype AnkB and AnkB p.S646F expressing cultures exhibited similar, low numbers of GFP-positive cells at 48 h after transfection, suggesting that the observed differences in viability and proliferation were not due to selective loss of transfected cells but rather to a population effect via paracrine communication. Cardiomyocytes are known to release "cardiokines" when under stress (as reviewed in Dewey et al. (2016) ). These cardiokines can impact proliferation, differentiation, and inflammation and can have both beneficial and detrimental effects, inhibiting and promoting apoptosis (as reviewed in Wu et al. (2018) ). Future work will examine the potential role for AnkB in regulating paracrine communication in H9c2 cells and cardiomyocytes. Additionally, given AnkB's role as a scaffold protein for several ion channels and receptors involved in regulating intracellular Ca 2+ homeostasis, AnkB is likely to be involved in the regulation of cellular viability.
The Ca 2+ dependence of key cell death or survival regulating proteins is well-known (as reviewed in Zhivotovsky and Orrenius (2011) ). Moreover, Ca 2+ also acts as an important factor in cellular development by regulating Ca 2+ -dependent gene expression mechanisms (Sheng et al. 1991; West et al. 2001; Hogan et al. 2003) raising the possibility that AnkB could similarly play a role in cardiomyocyte development. Our results showing that AnkB p.S646F was less stable only in undifferentiated H9c2 cells suggest the impact of the p.S646F variant occurs during cellular development and thus could impact on the overall structural and functional development of the heart. Ultimately, the impact of AnkB p.S646F on AnkB stability and H9c2 cell survival provides additional insight into the potential etiology of cardiac dysfunction observed in patients.
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